- Overview
- Products
- Casting & Splinting
- Hand Hygiene
- Patient Monitoring
- Securement and Immobilization
- Skin & Wound Care
- Sterilization & Monitoring
- Surgical Solutions
- Vascular Access
- View All Products
- Conditions
- Adhesive Skin Damage
- Bloodstream Infections
- Venous Leg Ulcer/ Edema Management
- Oncology Care
- Securement
- Skin Care
- I.V. Device Disinfection
- Surgical Site Infections
- Vascular Access Securement Dressings & Devices
- Wound Management
- Education
- Support
-
New data from a randomized controlled trial with at-risk patients further affrms that Prevena Therapy significantly reduces the risk of 90-day surgical site complications (SSCs) and readmissions, when compared with the current standard of care (SOC). In fact, the evidence supporting the efficacy of Prevena Therapy was so strong that the study was terminated before its planned completion.¹
-
Reduction in SSCs*3.4% (5/147) Prevena Therapy vs.14.3% (21/47) SOC
(p=0.0013)* -
Reduction in readmission rates*
3.4% (5/147) Prevena Therapy vs.
10.2% (21/47) SOC
(p=0.0208)* -
Fewer mean dressing changes*
1.1+ 0.3 (5/147) Prevena Therapy vs.
1.3+ 1.0 (21/47) SOC
(p=0.0003)*
-
*Calculation(s) are derived based on relative patient group incidence rate reported in this study. *Statistically significant (p=< 0.05)
-
1. Higuera-Rueda C, Emara AK, Nieves-Malloure Y, Klika AK, Cooper HJ, Cross MB, Guild GN, Nam D, Nett M, Scuderi GR, Cushner FD, Piuzzi NS, Silverman RP. The Effectiveness of Closed Incision Negative Pressure Therapy versus Silver-Impregnated Dressings in Mitigating Surgical Site Complications in High-Risk Patients after Revision Knee Arthroplasty: The PROMISES Randomized Controlled Trial. J Arthroplasty (2021), doi: https://doi.org/10.1016/j.arth.2021.02.076
Our apologies...
An error has occurred while submitting. Please try again later...
Thank you!
Your form was submitted successfully
The Power of PREVENA™ Therapy
-
PREVENA™ Therapy can aid in reducing the costly financial burden of complications such as SSI’s.
-
PREVENA™ Therapy is the first and only medical device indicated by FDA to help reduce superficial surgical site infections in high-risk patients in Class I and II wounds*
-
The most clinically validated closed incision negative pressure therapy with over 80+ publications and growing
-
*The effectiveness of 3M™ Prevena™ Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at 3M.com.
PREVENA™ Therapy is uniquely engineered to empower incision management that works to protect patients, surgeons, staff, practices, and hospitals during the SARS-CoV-2 pandemic.
-
Orthopedic Outcomes -
Vascular Outcomes -
Plastic Outcomes
-
PREVENA™ Therapy for PatientsAccess information and patient stories to share with your patients.
-
Medical Education
Call us on +852-2806-6111
Call us on +852-2806-6111
Our apologies...
An error has occurred while submitting. Please try again later...
Thank you!
Your form was submitted successfully
-
*PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units are intended to aid in reducing the incidence of seroma and, in patients at risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and II wounds. The effectiveness of PREVENA™ Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at ##discLink1##.
